E-LIB Suche - Ergebnisse für: Hurvitz, S.A

1

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2..:

Hurvitz, S.A. ; Kim, S.-B. ; Chung, W.-P....
ESMO Open. 9 (2024) 5 - p. 102924 , 2024

Link: https://doi.org/10.1016/..

2

218P Vepdegestrant, a proteolysis targeting chimera (PROTAC..:

Hamilton, E.P. ; Hurvitz, S.A. ; McAndrew, N.P....
ESMO Open. 9 (2024) - p. 103240 , 2024

Link: https://doi.org/10.1016/..

3

277P Descriptive analysis of hepatic safety for patients (p..:

Harbeck, N. ; Jacot, W. ; Ezquerra, M. Bellet...
ESMO Open. 9 (2024) - p. 103335 , 2024

Link: https://doi.org/10.1016/..

4

189P The impact of high body mass index (BMI) on the safety..:

Estevez, L. García ; Bardia, A. ; Rugo, H.S....
ESMO Open. 9 (2024) - p. 103211 , 2024

Link: https://doi.org/10.1016/..

5

186P Exploratory pooled safety analysis of trastuzumab deru..:

Park, Y.H. ; Jacot, W. ; Hurvitz, S.A....
ESMO Open. 9 (2024) - p. 103208 , 2024

Link: https://doi.org/10.1016/..

6

Abemaciclib plus a nonsteroidal aromatase inhibitor as init..:

Goetz, M.P. ; Toi, M. ; Huober, J....
Annals of Oncology. , 2024

Link: https://doi.org/10.1016/..

7

250P Evolution of characteristics, real-world (rw) treatmen..:

Punie, K. ; Kurian, A.W. ; Ntalla, I...
ESMO Open. 9 (2024) - p. 103271 , 2024

Link: https://doi.org/10.1016/..

8

154TiP TACTIVE-N: Open-label, randomized, noncomparative ne..:

Fasching, P.A. ; Clifton, K. ; Katashvili, Z....
ESMO Open. 8 (2023) 1 - p. 101493 , 2023

Link: https://doi.org/10.1016/..

9

201P Trilaciclib combined with sacituzumab govitecan (SG) i..:

Seneviratne, L. ; Harnden, K.K. ; Mardones, M....
ESMO Open. 8 (2023) 1 - p. 101390 , 2023

Link: https://doi.org/10.1016/..

10

P253 ARV-471, a PROTAC® estrogen receptor (ER) degrader in ..:

Hurvitz, S.A ; Schott, A.F ; Ma, C....
The Breast. 68 (2023) - p. S116 , 2023

Link: https://doi.org/10.1016/..

11

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2..:

Jhaveri, K. ; Eli, L.D. ; Wildiers, H....
Annals of Oncology. 34 (2023) 10 - p. 885-898 , 2023

Link: https://doi.org/10.1016/..

12

Corrigendum to "Tucatinib versus placebo added to trastuzum..:

Curigliano, G. ; Mueller, V. ; Borges, V....
Annals of Oncology. 34 (2023) 7 - p. 630 , 2023

Link: https://doi.org/10.1016/..

13

205P VERITAC update: Phase II study of ARV-471, a PROteolys..:

Hurvitz, S.A. ; Schott, A. ; Ma, C.X....
ESMO Open. 8 (2023) 1 - p. 101394 , 2023

Link: https://doi.org/10.1016/..

14

257TiP VERITAC-2: A global, randomized phase III study of A..:

Hamilton, E. ; Ma, C.X. ; De Laurentiis, M....
ESMO Open. 8 (2023) 1 - p. 101445 , 2023

Link: https://doi.org/10.1016/..

15

Tucatinib versus placebo added to trastuzumab and capecitab..:

Curigliano, G. ; Mueller, V. ; Borges, V....
Annals of Oncology. 33 (2022) 3 - p. 321-329 , 2022

Link: https://doi.org/10.1016/..